In a proportion of patients with chronic myeloid leukemia (CML) being treated with dasatinib, we recently observed large granular lymphocyte (LGL) expansions carrying clonal T-cell receptor (TCR) γ/δ gene rearrangements. To assess the prevalence and role of clonal lymphocytes in CML, we collected samples from patients (n = 34) at the time of diagnosis and during imatinib and dasatinib therapies and analyzed lymphocyte clonality with a sensitive polymerase chain reaction–based method of TCR γ and δ genes. Surprisingly, at CML diagnosis, 15 of 18 patients (83%) had a sizeable clonal, BCR-ABL1 negative lymphocyte population, which was uncommon in healthy persons (1 of 12; 8%). The same clone persisted at low levels in most imatinib-treated patients. In contrast, in a distinct population of dasatinib-treated patients, the diagnostic phase clone markedly expanded, resulting in absolute lymphocytosis in blood. Most patients with LGL expansions (90%) had TCR δ rearrangements, which were uncommon in patients without an LGL expansion (10%). The TCR δ clones were confined to γδ+ T- or natural killer–cell compartments and the TCR γ clones to CD4+/CD8+ αβ+ fractions. The functional importance of clonal lymphocytes as a part of leukemia immune surveillance and the putative anergy-reversing role of dasatinib require further evaluation.

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by Philadelphia chromosome (Ph) leading to the formation of oncogenic BCR-ABL1 fusion gene and autonomously active tyrosine kinase enzyme. Current therapy for CML is based on tyrosine kinase inhibitor (TKI) treatment with a favorable outcome both in the first-line setting with imatinib (Glivec; Novartis)1,2  and in the second-line setting with dasatinib (Sprycel; Bristol-Myers Squibb)3,4  or nilotinib (Tasigna; Novartis).5  In addition to the intended target kinase, BCR-ABL1, second-generation TKIs (dasatinib in particular) also inhibit a wide variety of other kinases such as SRC and TEC kinases6,8  known to be key regulators of immune responses. Recent in vitro studies have shown that dasatinib,9,,,13  imatinib,14,,17  and nilotinib18  have inhibitory effects on T-cell proliferation and activation. However, the effects of dasatinib were found to be more profound, probably through stronger SRC-kinase inhibition. The drug blocked T-cell proliferation, activation, cell cycle, secretion of various proinflammatory cytokines and interrupted signaling through T-cell receptor (TCR). Dasatinib did not, however, induce apoptosis; therefore, the T-cell viability was unaffected.9,11,12,16,19  In patients, no clinical signs of immunosuppression have been observed during imatinib treatment to date. One earlier study reported a modestly increased incidence of varicella-zoster virus infections during imatinib treatment.20  In the setting after allogeneic stem cell transplantation, imatinib treatment may even have an additive effect to the donor lymphocyte infusions.21  Similarly, in large phase 2/3 clinical studies with dasatinib no increased rates of infections were observed.22,23  However, a recent case report suggested that in some patients with advanced CML, high-dose dasatinib therapy may be associated with opportunistic infections due to Epstein-Barr virus and Pneumocystis jiroveci.24 

Recent findings from our and other groups have shown that, in a distinct subgroup of patients with CML and Ph+ acute lymphoblastic leukemia, dasatinib therapy is associated with a chronic monoclonal/oligoclonal large granular lymphocyte (LGL) lymphocytosis in peripheral blood.25,26  Dasatinib-associated lymphocytosis (peak lymphocyte count ranging from 4 to 20 × 109/L) developed at an average of 3 months after the start of treatment and persisted throughout therapy. The expanded lymphocytes had either a CD3+CD8+ effector memory T-cell or a CD3negCD16/CD56+ natural killer (NK)–cell phenotype. Strikingly, the clonal LGL lymphocytosis was associated with exceptional, durable therapy responses in patients with advanced, poor-prognosis Ph+ leukemia.

Monoclonal and oligoclonal T-cell expansions are common during a primary immune response against viral antigens (eg, HIV, cytomegalovirus [CMV]).27,29  Clonal expansions of cytotoxic cells have also been observed in the context of hematologic malignancies, such as multiple myeloma,30  myelodysplastic syndrome,31  and acute promyelocytic leukemia,32  and have been linked to cancer immune surveillance. Small numbers of clonal and persistent CD4+ and CD8+ cells have been shown to exist in healthy persons and become more common with advanced age. This phenomenon has been attributed to dysregulated systemic immunity in the elderly (immunosenescence).33 

Prevalence, detailed molecular background, and clinical implications of clonal lymphocytes in CML are currently unknown, as well as their association to TKI therapy. The aim of this study was to comprehensively analyze lymphocyte clonality and evolution of clones in patients with CML at diagnosis and during TKI therapy. Unexpectedly, clonal lymphocytes were observed in most patients with CML already at diagnosis, they persisted during imatinib therapy at low levels, and expanded during dasatinib therapy. On the basis of the association of clonal LGL expansion to favorable disease outcome, we hypothesize that, by inhibiting distinct off-target kinases in immune effector cells, dasatinib may restore the function of anergic, exhausted leukemia-specific cytotoxic lymphocytes present already at the time of CML diagnosis.

Study patients and samples

The study population included patients with CML (n = 34) on dasatinib (n = 20) and imatinib (n = 14) therapies. All patients with CML treated with dasatinib from our center (Helsinki University Central Hospital) were included in the study together with 5 additional patients on dasatinib therapy from other centers. Similarly, all patients with CML treated with imatinib from whom we had both diagnostic phase and follow-up samples available were included in the study. Of the 20 patients treated with dasatinib, 10 patients had lymphocyte expansion with LGL morphology during therapy (peak count range, 4-20 × 109/L). The main characteristics of the patients are summarized in Table 1. Blood cell counts, differential analysis of leukocytes, and the presence of antibodies to CMV in the blood (CMV serology) were obtained from routine laboratory tests.

Table 1

Patient characteristics (n = 34)

Patient no.DiagnosisAge, y*SexTherapyResponseDuration, moLGL lymphocytosisCMV serology
CML BC 62 Dasatinib CMR 16 Yes Pos 
CML BC 43 Dasatinib CMR 45 Yes Pos 
CML AP 74 Dasatinib CHR 57 Yes Pos 
CML CP 53 Dasatinib CCgR Yes Pos 
CML CP 65 Dasatinib MMR 36 Yes Pos 
CML CP 58 Dasatinib CMR 48 Yes Pos 
CML CP 61 Dasatinib CCgR 12 Yes ND 
CML CP 52 Dasatinib CMR Yes Pos 
CML CP 60 Dasatinib CMR 39 Yes Pos 
10 CML CP 76 Dasatinib CMR 59 Yes Pos 
11 CML BC 68 Dasatinib PHR No ND 
12 CML CP 29 Dasatinib CMR 58 No Pos 
13 CML CP 64 Dasatinib MMR 37 No Neg 
14 CML CP 51 Dasatinib CMR 41 No ND 
15 CML CP 27 Dasatinib MMR 22 No Neg 
16 CML CP 40 Dasatinib MMR 54 No Neg 
17 CML CP 45 Dasatinib CCgR 12 No Pos 
18 CML CP 49 Dasatinib CCgR 57 No Pos 
19 CML CP 61 Dasatinib CMR 25 No Neg 
20 CML CP 78 Dasatinib CCgR No Pos 
21 CML CP 22 Imatinib CMR 31 No Pos 
22 CML CP 53 Imatinib CMR 27 No Pos 
23 CML CP 66 Imatinib CMR 48 No Pos 
24 CML CP 36 Imatinib CCgR 60 No Pos 
25 CML CP 40 Imatinib MMR 49 No Neg 
26 CML CP 43 Imatinib CCgR 27 No Pos 
27 CML CP 48 Imatinib CMR 52 No Pos 
28 CML CP 49 Imatinib CMR 58 No ND 
29 CML CP 49 Imatinib MMR 53 No ND 
30 CML CP 52 Imatinib CCgR 26 No Pos 
31 CML CP 59 Imatinib CMR 16 No Neg 
32 CML CP 58 Imatinib CMR 51 No Pos 
33 CML CP 61 Imatinib MMR 25 No Pos 
34 CML CP 59 Imatinib MMR 63 No Pos 
Patient no.DiagnosisAge, y*SexTherapyResponseDuration, moLGL lymphocytosisCMV serology
CML BC 62 Dasatinib CMR 16 Yes Pos 
CML BC 43 Dasatinib CMR 45 Yes Pos 
CML AP 74 Dasatinib CHR 57 Yes Pos 
CML CP 53 Dasatinib CCgR Yes Pos 
CML CP 65 Dasatinib MMR 36 Yes Pos 
CML CP 58 Dasatinib CMR 48 Yes Pos 
CML CP 61 Dasatinib CCgR 12 Yes ND 
CML CP 52 Dasatinib CMR Yes Pos 
CML CP 60 Dasatinib CMR 39 Yes Pos 
10 CML CP 76 Dasatinib CMR 59 Yes Pos 
11 CML BC 68 Dasatinib PHR No ND 
12 CML CP 29 Dasatinib CMR 58 No Pos 
13 CML CP 64 Dasatinib MMR 37 No Neg 
14 CML CP 51 Dasatinib CMR 41 No ND 
15 CML CP 27 Dasatinib MMR 22 No Neg 
16 CML CP 40 Dasatinib MMR 54 No Neg 
17 CML CP 45 Dasatinib CCgR 12 No Pos 
18 CML CP 49 Dasatinib CCgR 57 No Pos 
19 CML CP 61 Dasatinib CMR 25 No Neg 
20 CML CP 78 Dasatinib CCgR No Pos 
21 CML CP 22 Imatinib CMR 31 No Pos 
22 CML CP 53 Imatinib CMR 27 No Pos 
23 CML CP 66 Imatinib CMR 48 No Pos 
24 CML CP 36 Imatinib CCgR 60 No Pos 
25 CML CP 40 Imatinib MMR 49 No Neg 
26 CML CP 43 Imatinib CCgR 27 No Pos 
27 CML CP 48 Imatinib CMR 52 No Pos 
28 CML CP 49 Imatinib CMR 58 No ND 
29 CML CP 49 Imatinib MMR 53 No ND 
30 CML CP 52 Imatinib CCgR 26 No Pos 
31 CML CP 59 Imatinib CMR 16 No Neg 
32 CML CP 58 Imatinib CMR 51 No Pos 
33 CML CP 61 Imatinib MMR 25 No Pos 
34 CML CP 59 Imatinib MMR 63 No Pos 

LGL indicates large granular lymphocyte; CMV, cytomegalovirus; BC, blast crisis; CMR, complete molecular response; AP, accelerated phase; CHR, complete hematologic response; CP, chronic phase; CCgR, complete cytogenetic response; MMR, major molecular response; ND, not done; and PHR, partial hematologic response.

*

Age at the time of first clonality analysis.

Ongoing therapy.

In addition, 12 healthy volunteers were included as a control group. This group consisted of 6 men (median age, 47 years; range, 28-66 years) and 6 women (median age, 45 years; range, 26-61 years). Provided that the blood counts were normal and with no symptoms of disease, the results from TCR rearrangement assays were not given to the participating volunteers, to prevent unnecessary anxiety from a putative finding of occult clonal lymphocytes with undetermined significance.

The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Helsinki University Central Hospital Ethics Committee. Written informed consents were obtained from all patients and healthy controls, either as part of clinical drug studies or separately.

Separation of mononuclear cells

Peripheral blood (PB) or bone marrow samples were collected from patients at diagnosis and/or during TKI treatment. PB and bone marrow mononuclear cells (MNCs) were separated with Ficoll gradient centrifugation (GE Healthcare). MNCs were stored as cell pellets in −80°C or in liquid nitrogen.

Selection of CD8+ cells

For selection of CD8+ cells, the PB MNCs were labeled with CD8 MicroBeads (Miltenyi Biotec) according to instructions provided by the manufacturer and separated with an AutoMACS cell sorter (Miltenyi Biotec).

Fluorescence-activated cell sorting

Approximately 10 million PB MNCs were stained with antibodies against the following antigens: CD45, CD3, CD8, CD16/CD56. Gates were set on live and CD45+ cells. Different lymphocyte populations were gated and sorted as follows: CD3+CD8neg (CD4+ T cells), CD3+CD8+ (CD8+ T cells), CD3negCD16/56+ (NK cells), and CD3negCD16/56neg (B cells) with FACSAria (Becton Dickinson). TCR αβ+ and TCR γδ+ T cells were stained with antibodies against the following antigens: CD45, CD3, TCR αβ, and TCR γδ. Lymphocyte populations were gated and sorted as the following: CD45+ CD3+ TCR αβ+, CD45+ CD3+ TCR αβ+, and CD45+ CD3neg. All antibodies were from Becton Dickinson. Purity of the sorted fractions was confirmed with flow cytometry to be close to 100%. Sorting strategy and purity of sorted cell fractions are shown in Figure 1.

Figure 1

Strategy of FACS of different lymphocyte populations and purity of sorted populations. (A-G) FACS of a patient with T-cell LGL lymphocytosis (patient no. 2; Table 1) and (H-J) of a patient with NK-cell lymphocytosis (patient no. 6; Table 1). To sort lymphocyte subpopulations, PB MNCs were stained with antibodies against the following antigens: CD45, CD3, CD8, CD16/CD56, TCR αβ, and TCR γδ. Gates were first set on live and CD45+ cells (gray). Then gating of NK- and T-cell populations were done from CD16/CD56 versus CD3 scatter (A,H). CD3+ T cells were further sorted into CD8neg and CD8+ populations (B) and into TCRαβ+ and TCRγδ+ T cells (E). Purity of respective sorted populations is presented (C,D,F,G,I,J).

Figure 1

Strategy of FACS of different lymphocyte populations and purity of sorted populations. (A-G) FACS of a patient with T-cell LGL lymphocytosis (patient no. 2; Table 1) and (H-J) of a patient with NK-cell lymphocytosis (patient no. 6; Table 1). To sort lymphocyte subpopulations, PB MNCs were stained with antibodies against the following antigens: CD45, CD3, CD8, CD16/CD56, TCR αβ, and TCR γδ. Gates were first set on live and CD45+ cells (gray). Then gating of NK- and T-cell populations were done from CD16/CD56 versus CD3 scatter (A,H). CD3+ T cells were further sorted into CD8neg and CD8+ populations (B) and into TCRαβ+ and TCRγδ+ T cells (E). Purity of respective sorted populations is presented (C,D,F,G,I,J).

Close modal

DNA extraction

Genomic DNA was isolated from fresh, frozen, or sorted MNCs by Blood DNA isolation Kit (MO BIO) or Genomic DNA from Tissue; NucleoSpin Tissue XS (Machery-Nagel). DNA concentration and purity were measured with NanoDrop (Thermo Scientific). DNA was stored at −20°C.

Fluorescence in situ hybridization

Fluorescence in situ hybridization (FISH) analyses were performed on sorted PB CD4+, CD8+, NK, and B cells from 2 patient in diagnostic phase (patients 7 and 17; Table 1). Analyses were done on interphase cells prepared on cytospin slides with the use of locus-specific dual-color, dual-fusion BCR-ABL probe mixture (Vysis). Hybridizations were performed according to the manufacturer's instructions.

Detection of TCR γ and δ gene rearrangements by polymerase chain reaction

TCR γ and δ gene rearrangements were studied by polymerase chain reaction (PCR) analysis with the use of 12 primer pairs for γ gene, and 6 primer pairs for δ genes allowing detection of most of the known TCR γ and δ gene rearrangements. The analysis was conducted according to the BIOMED-1 PCR protocol.34  PCR was performed in the PTC-200 Peltier Thermal Cycler (Bio-Rad).

After PCR amplification of the TCR δ and γ genes, the clonality was confirmed by heteroduplex analysis. PCR products were denaturated at 95°C for 5 minutes, followed by a rapid random renaturation at 4°C for 1 hour. PCR products were separated by electrophoresis on a commercial 5% Criterion polyacrylamide gel (Bio-Rad) in 1× [Tris (tris(hydroxymethyl) aminomethane) borate EDTA (ethylenediaminetetraacetic acid)] buffer. Gels were stained with EtBr and visualized with ultraviolet illumination. Positive findings were cut from the gel and if necessary reamplified with the same set of primers as were used before sequencing. Lower detection limit of the assay is 1% to 5% of clonal cells among polyclonal lymphocytes.

Sequencing of the junctions in TCR γ and δ gene rearrangements

Clonal products were sequenced with BigDye Version 1.1 Cycle Sequencing kit (Applied Biosystems).

Sequencing was performed in the ABI PRISM 310 Genetic Analyzer and sequences were analyzed with the use of the IMGT Database35  (http://www.imgt.org/) and the Blast search.36 

Unequivocal sequencing and junction region analysis were obtained for all clonal products, except for 4 clonal TCR γ products that presented as single clonal products on polyacrylamide gel electrophoresis gels, but sequencing disclosed a chromatogram pattern in the junction region compatible with a biallelic product. Determination of functionality for these TCR γ rearrangements thus was not possible.

Design of individual allele-specific oligonucleotide primers and quantification of clones with real-time quantitative PCR

Patient-specific allele-specific oligonucleotide (ASO) primers for real-time quantitative PCR (RQ-PCR) were designed with Primer Express software (Applied Biosystems). For each patient, if possible, 2 targets (TCR γ and TCR δ) were selected for ASO-PCR purposes. ASO primers were designed to match the hypervariable junction regions of the sequenced TCR δ and TCR γ gene rearrangements. Forward ASO primers were used in TaqMan RQ-PCR analysis in conjunction with a consensus reverse primer and a TaqMan probe selected according to the D or J gene present in the rearrangement (reverse primer and probe sequences available from the authors on request). DNA was amplified in triplicate reactions with the use of TaqMan Universal PCR Mastermix (Applied Biosystems) and the individual ASO primer with a consensus primer and a TaqMan probe. RQ-PCR was performed in the 7500 Real Time PCR system (Applied Biosystems), and the thermocycling conditions consisted of an initial step at 50°C for 2 minutes and denaturation step at 95°C for 10 minutes, followed by 50 cycles at 95°C for 15 seconds and at 60°C for 60 seconds.

Standard curves were prepared by diluting a patient DNA sample in polyclonal DNA from healthy donors. A sample with good quality and high amount of DNA, and with confirmed presence of the clonal rearrangement, was used as a reference sample. The ratio of the specific clonally rearranged DNA relative to albumin DNA as measured by RQ-PCR was defined to be 1.0 in the reference samples. The reference sample dilution series for the RQ-PCR standard curve was prepared by 10-fold dilutions. Thus, the amount of DNA with the specific clonal rearrangement relative to the amount of albumin DNA could be measured in all follow-up samples with the use of the reference sample as standard. The measurement scales were completely individual for each clone and for each patient. The purpose of these measurements was to detect relative changes in serial measurements.

The sensitivity of each allele-specific RQ-PCR analysis was estimated from the reference sample dilution series. Sensitivity was defined to be the lowest dilution still giving specific amplification. When determined this way the sensitivity estimate depends on 3 factors: (1) quality of DNA in the reference sample, (2) efficiency of each allele-specific RQ-PCR reaction, and (3) the unknown proportion of clonal cells representing that specific clone in the reference sample. With standard DNA extraction and standard rules for primer design the factors (1) and (2) remain similar for different allele-specific PCR targets. Therefore, a high sensitivity would suggest a high proportion of clonally rearranged cells in the reference sample, whereas a poor sensitivity suggests a low proportion of cells with specific clonal rearrangement in the reference sample.

BCR-ABL1–negative lymphocyte clones are common in patients with CML at diagnosis

Clonality of the lymphocytes was determined by PCR and gel analysis with the use of 12 primer pairs for the TCR γ gene rearrangements and 6 primer pairs for TCR δ gene rearrangements. If a positive product was observed in the gel (Figure 2), it was confirmed by sequencing. Of 12 healthy controls studied, only one female had a sequencing-confirmed clonal TCR γ gene rearrangement. This healthy person was asymptomatic and had normal blood counts. No clonal TCR δ gene rearrangements were detected in any healthy volunteers. In contrast, 15 of 18 (83%) patients with chronic phase CML showed clonal TCR rearrangements at the time of diagnosis. Ten patients had clonal rearrangements only in the TCR γ gene, whereas 5 patients had rearrangements both in TCR γ and δ genes, with the latter being a minority (18% of all rearrangements detected) (Table 2). Most patients displayed more than one clonal TCR rearrangement. The sensitivity of the assay is 1% to 5% of clonal cells, indicating that a significant proportion of diagnostic phase lymphocytes are clonal in untreated patients with CML. In 3 patients no clonal rearrangements could be detected at diagnosis with the set of primers used in this study.

Figure 2

TCRγ rearrangements at the diagnosis and during TKI therapy. Clonality of the lymphocytes was determined by PCR and gel analysis with the use of 12 primer pairs for the TCR γ gene rearrangements and 6 primer pairs for TCR δ gene rearrangements. After PCR amplification and heteroduplex treatment, the PCR products were separated by electrophoresis on a 5% Criterion gel. Gels were stained with EtBr and visualized with ultraviolet illumination. (A) Dasatinib-treated patient with LGL lymphocytosis showing clonal PCR products (white arrow) of the primer pair TCRγ 12 at diagnosis and during dasatinib therapy. Lane 2 indicates at diagnosis; lane 3, 6 months after start of dasatinib therapy during lymphocytosis; lane 4, pool of healthy controls showing polyclonal smear; lane 5, water control. (B) Imatinib-treated patient without lymphocytosis showing clonal PCR product (white arrow) of the primer pair TCRγ 6 at diagnosis. After 12 months of imatinib therapy, no clonal band was visible. Lane 2 indicates at diagnosis; lane 3, 12 months after start of imatinib therapy; lane 4, pool of healthy controls showing polyclonal smear; lane 5, water control. Positive findings were confirmed with sequencing. Vertical lines have been inserted to indicate a repositioned gel lane (DNA ladder).

Figure 2

TCRγ rearrangements at the diagnosis and during TKI therapy. Clonality of the lymphocytes was determined by PCR and gel analysis with the use of 12 primer pairs for the TCR γ gene rearrangements and 6 primer pairs for TCR δ gene rearrangements. After PCR amplification and heteroduplex treatment, the PCR products were separated by electrophoresis on a 5% Criterion gel. Gels were stained with EtBr and visualized with ultraviolet illumination. (A) Dasatinib-treated patient with LGL lymphocytosis showing clonal PCR products (white arrow) of the primer pair TCRγ 12 at diagnosis and during dasatinib therapy. Lane 2 indicates at diagnosis; lane 3, 6 months after start of dasatinib therapy during lymphocytosis; lane 4, pool of healthy controls showing polyclonal smear; lane 5, water control. (B) Imatinib-treated patient without lymphocytosis showing clonal PCR product (white arrow) of the primer pair TCRγ 6 at diagnosis. After 12 months of imatinib therapy, no clonal band was visible. Lane 2 indicates at diagnosis; lane 3, 12 months after start of imatinib therapy; lane 4, pool of healthy controls showing polyclonal smear; lane 5, water control. Positive findings were confirmed with sequencing. Vertical lines have been inserted to indicate a repositioned gel lane (DNA ladder).

Close modal
Table 2

Clonal TCR rearrangements in patients with CML at diagnosis and during follow-up samples (n = 18)

Patient no.Date, ddmmmyyTCR δ primer pairs
TCR γ primer pairs
123456123456789101112
5                    
    Diagnosis 03MAR05     X*     X*         
    Dasatinib 11FEB08     X*     X*        
7                    
    Diagnosis 31MAR09  X*              X* 
    Dasatinib 29SEP09  X*                X* 
15                    
    Diagnosis 18AUG05                   
    Dasatinib 24JUL08                   
17                    
    Diagnosis 30MAR09                  
    Dasatinib 29SEP09                 
21                    
    Diagnosis 12MAR07          X*         
    Imatinib 14JAN08          X*         
22                    
    Diagnosis 15NOV06         X*        
    Imatinib 15OCT07           X*        
23                    
    Diagnosis 04OCT05                  
    Imatinib 01MAR06                   
24                    
    Diagnosis 03FEB06                   
    Imatinib 13SEP06                   
25                    
    Diagnosis 26JAN06                 
    Imatinib 01FEB07                   
26                    
    Diagnosis 04DEC07                   
    Imatinib 20NOV08                   
27                    
    Diagnosis 13OCT05                  
    Imatinib 12FEB07                  
28                    
    Diagnosis 24MAY05                  
    Imatinib 04OCT07                  
29                    
    Diagnosis 20JUL05                  
    Imatinib 13MAR07                   
30                    
    Diagnosis 11JAN07      X*            
    Imatinib 17APR08       X*          
31                    
    Diagnosis 14FEB07       X*            
    Imatinib 07JAN08       X*            
32                    
    Diagnosis 14SEP05           X*       
    Imatinib 20FEB07           X*        
33                    
    Diagnosis 19FEB07             X*    
    Imatinib 30JUN08               X*    
34                    
    Diagnosis 28SEP04         X*        
    Imatinib 14SEP05           X*        
Patient no.Date, ddmmmyyTCR δ primer pairs
TCR γ primer pairs
123456123456789101112
5                    
    Diagnosis 03MAR05     X*     X*         
    Dasatinib 11FEB08     X*     X*        
7                    
    Diagnosis 31MAR09  X*              X* 
    Dasatinib 29SEP09  X*                X* 
15                    
    Diagnosis 18AUG05                   
    Dasatinib 24JUL08                   
17                    
    Diagnosis 30MAR09                  
    Dasatinib 29SEP09                 
21                    
    Diagnosis 12MAR07          X*         
    Imatinib 14JAN08          X*         
22                    
    Diagnosis 15NOV06         X*        
    Imatinib 15OCT07           X*        
23                    
    Diagnosis 04OCT05                  
    Imatinib 01MAR06                   
24                    
    Diagnosis 03FEB06                   
    Imatinib 13SEP06                   
25                    
    Diagnosis 26JAN06                 
    Imatinib 01FEB07                   
26                    
    Diagnosis 04DEC07                   
    Imatinib 20NOV08                   
27                    
    Diagnosis 13OCT05                  
    Imatinib 12FEB07                  
28                    
    Diagnosis 24MAY05                  
    Imatinib 04OCT07                  
29                    
    Diagnosis 20JUL05                  
    Imatinib 13MAR07                   
30                    
    Diagnosis 11JAN07      X*            
    Imatinib 17APR08       X*          
31                    
    Diagnosis 14FEB07       X*            
    Imatinib 07JAN08       X*            
32                    
    Diagnosis 14SEP05           X*       
    Imatinib 20FEB07           X*        
33                    
    Diagnosis 19FEB07             X*    
    Imatinib 30JUN08               X*    
34                    
    Diagnosis 28SEP04         X*        
    Imatinib 14SEP05           X*        

Clonality of the lymphocytes was determined by PCR and gel analysis with the use of 12 primer pairs for the TCR γ gene rearrangements and 6 primer pairs for TCR δ gene rearrangements. Positive clonal PCR products were confirmed with the sequencing and are marked in the columns as X.

*

Identical rearrangements at the diagnosis and follow-up sample.

Lymphocyte clones detected at diagnosis persist during TKI therapy

From 15 patients with CML, who had clonal lymphocytes at diagnosis, a follow-up sample during dasatinib or imatinib therapy was available for analysis (Table 2). TCR γ and δ gene rearrangements were searched from the follow-up samples with the use of a similar approach as from the diagnostic phase samples (PCR and gel analysis followed by confirmation of positive PCR products with sequencing). All 3 patients taking dasatinib and 10 of 12 patients taking imatinib (83%) who had clonal lymphocytes at diagnosis also had confirmed clonal TCR γ/δ rearrangements during TKI therapy (Figure 2; Table 2). In 9 of 13 cases (69%) the clone found in the follow-up sample was identical with the diagnostic phase clone (Table 2). No clonal δ gene rearrangements could be detected during imatinib therapy. None of the patients taking imatinib with lymphocyte clones had increased absolute lymphocyte counts during therapy.

In 3 patients without any confirmed clonal TCR γ/δ rearrangements at diagnosis (patients 15, 24, and 26; Table 2), no clonal products were found in samples during TKI treatment either.

Analysis of TCR γ and TCR δ gene rearrangements in patients treated with dasatinib patients

In our previous study, we showed that in a proportion of patients treated with dasatinib, an expansion of T or NK cells occurs during the therapy.26  In patients with T-cell expansions, we detected clonal TCR γ/δ gene rearrangements. We now used a more sensitive PCR-heteroduplex method to determine the prevalence of clonal lymphocytes in patients with (n = 10) and without lymphocytosis (n = 10) treated with dasatinib. Clonal lymphocytes were found in all patients who developed LGL lymphocytosis during dasatinib therapy (LGLpos) (Table 3). This included also patients with expansion of NK cells (n = 6). The frequency of clonal TCR γ/δ gene rearrangements in patients taking dasatinib without LGL lymphocytosis (LGLneg) was 70% (Table 3), similar to that of patients taking imatinib (64%; Table 2).

Table 3

Clonal TCR rearrangements in patients treated with dasatinib (n = 20)

Patient no.Immunophenotype of LGL cellsTCR δ primer pairs
TCR γ primer pairs
123456123456789101112
T and NK cell                 
T cell             
T cell                 
NK cell                
T and NK cell                
NK cell                  
T and NK cell                 
T cell                 
T cell                
10 NK cell                 
11                 
12                   
13                   
14                 
15                    
16                    
17                  
18                  
19                    
20                   
Patient no.Immunophenotype of LGL cellsTCR δ primer pairs
TCR γ primer pairs
123456123456789101112
T and NK cell                 
T cell             
T cell                 
NK cell                
T and NK cell                
NK cell                  
T and NK cell                 
T cell                 
T cell                
10 NK cell                 
11                 
12                   
13                   
14                 
15                    
16                    
17                  
18                  
19                    
20                   

Patients 1 to 10 had persistent lymphocytosis with large granular lymphocyte (LGL) morphology during dasatinib treatment. In patients 11 to 20 lymphocyte counts were normal during therapy. Clonality of the lymphocytes was determined by PCR and gel analysis with the use of 12 primer pairs for the TCR γ gene rearrangements and 6 primer pairs for TCR δ gene rearrangements. Positive clonal PCR products were confirmed with the sequencing and are marked in the columns as X.

Clonal rearrangements in TCR δ gene were found in most patients with LGLpos (90%), whereas only 1 patients with LGLneg had clonal TCR δ gene rearrangement (10%). No clear difference in the frequency of TCR γ gene rearrangements (90% vs 70%) was detected.

Correlation between absolute lymphocyte count and relative proportion of lymphocyte clone

In patients taking dasatinib with LGL lymphocytosis, the lymphocyte counts fluctuated markedly during the therapy. To quantify the amount of lymphocyte clone in correlation to the lymphocyte count, we designed ASO-primers for 4 LGLpos and 2 LGLneg patients. Estimation of the amount of the existing clone was determined by designating one follow-up sample with a reference value of 1 and by calculating other follow-up samples in relation to this reference sample. This method allowed quantitative comparison of the clone in different time points but not between different clones. The median follow-up time during dasatinib treatment was 21 months (range, 8-41 months).

Quantitative follow-up of LGLpos patients showed that the expansion of 1 to 2 predominant lymphocyte clones accounted for LGL lymphocytosis (Figure 3) in most cases. In addition, a few minor clones were often present. Although the method did not allow to determine the absolute amount of the clone from the total lymphocytes, the sensitivity of the assay in some patients with LGL lymphocytosis (1:10 000) suggested that the majority of the analyzed cells belonged to this clone. In patients without LGL lymphocytosis, the amount of clone varied slightly but did account for the variations in the absolute lymphocyte count, suggesting that it was only a minor subpopulation of all lymphocytes (data not shown).

Figure 3

Quantitative follow-up of lymphocyte clone with individual ASO primers. Patient-specific primers were designed to recognize clonal TCR γ and TCR δ gene rearrangements and were used to estimate the amount of clone in various time points before and during dasatinib therapy. The estimation of the amount of the existing clone was determined by designating one follow-up sample with a reference value of 1, and calculating other follow-up samples in relation to this reference sample. Figures on the left side show the estimated amount of clone in the blood at different time points (reference level 1 is marked with dashed black line). The figure on the right side presents the absolute lymphocyte counts at the same time points (upper limit of normal lymphocyte count is marked with dashed black line). (A) Patient 1 (Tables 1,4). This patient had a clonal rearrangement in TCR γ gene that was detected in CD8+αβ+ T cells, whereas the clonal rearrangement in TCR δ gene was found in NK cells. Follow-up of these 2 clones was done before (day −103, on imatinib) and after start of dasatinib therapy (days 56, 117, and 138). (B) Patient 5 (Tables 1,4). This patient had a clonal rearrangement in TCR γ gene detected in CD4+αβ+ T cells, whereas the clonal rearrangement in TCR δ gene was found in CD4+γδ+ T cells. Follow-up samples were available from the time of diagnosis (day −739) and during imatinib (day −187) and dasatinib (days 29, 239, 336, and 351) therapy.

Figure 3

Quantitative follow-up of lymphocyte clone with individual ASO primers. Patient-specific primers were designed to recognize clonal TCR γ and TCR δ gene rearrangements and were used to estimate the amount of clone in various time points before and during dasatinib therapy. The estimation of the amount of the existing clone was determined by designating one follow-up sample with a reference value of 1, and calculating other follow-up samples in relation to this reference sample. Figures on the left side show the estimated amount of clone in the blood at different time points (reference level 1 is marked with dashed black line). The figure on the right side presents the absolute lymphocyte counts at the same time points (upper limit of normal lymphocyte count is marked with dashed black line). (A) Patient 1 (Tables 1,4). This patient had a clonal rearrangement in TCR γ gene that was detected in CD8+αβ+ T cells, whereas the clonal rearrangement in TCR δ gene was found in NK cells. Follow-up of these 2 clones was done before (day −103, on imatinib) and after start of dasatinib therapy (days 56, 117, and 138). (B) Patient 5 (Tables 1,4). This patient had a clonal rearrangement in TCR γ gene detected in CD4+αβ+ T cells, whereas the clonal rearrangement in TCR δ gene was found in CD4+γδ+ T cells. Follow-up samples were available from the time of diagnosis (day −739) and during imatinib (day −187) and dasatinib (days 29, 239, 336, and 351) therapy.

Close modal

Clonal lymphocyte population existed before dasatinib therapy

DNA samples before the start of dasatinib therapy were available from 5 patients with LGL lymphocytosis. Intriguingly, quantitative follow-up of lymphocyte clones by PCR showed that in all patients the observed clones existed at low levels already before the start of dasatinib therapy during imatinib treatment, but no lymphocyte expansions were then seen. In addition, from 2 patients diagnostic phase samples were available, and the analysis with the patient-specific ASO primers confirmed that the same clone, which expanded during dasatinib treatment, was already present at diagnosis. In patient no. 5, the percentage of the clone was high in the diagnostic phase sample and then subsequently decreased during imatinib therapy. After initiation of dasatinib treatment, the amount of the clone increased again together with increases in the lymphocyte count (Figure 3B).

One patient with persistent NK-cell lymphocytosis during dasatinib therapy discontinued the treatment because of adverse effects (patient 4; Table 1). In the blood sample after 4 years of discontinuation, the earlier expanded NK clone (Table 4) was still present when analyzed with the patient specific primers. However, lymphocyte count and distribution had normalized after discontinuation of dasatinib.

Table 4

Quantitative follow-up and FACS sorting of lymphocytes with individual allele-specific oligonucleotide (ASO) primer

Patient no.LGL lymphocytosisGeneQuantitative follow-upLymphocyte populationCell-surface TCR expression
Yes Incomplete TCRD Yes NK cell NA 
Yes Complete TCRG Yes CD8+ T cell TCR αβ+ 
Yes Incomplete TCRD Yes CD8+ T cell ND 
Yes Complete TCRD Yes CD8+ T cell TCR γδ+ 
Yes Complete TCRG Yes CD4+ T cell TCR αβ+ 
Yes Complete TCRG Yes CD4+ T cell ND 
Yes Incomplete TCRD No NK cell NA 
Yes Incomplete TCRD Yes CD4+ T cell TCR γδ+ 
Yes Complete TCRG Yes CD4+ T cell TCR αβ+ 
Yes Incomplete TCRD No NK cell NA 
Yes Incomplete TCRD No NK cell NA 
Yes Complete TCRG Yes CD8+ T cell ND 
10 Yes Incomplete TCRD No ND ND 
10 Yes Complete TCRG No CD8+ T cell ND 
12 No Complete TCRG Yes ND ND 
17 No Complete TCRG No CD8+ T cell ND 
18 No Complete TCRG Yes CD8+ T cell ND 
18 No Complete TCRG Yes CD8+ T cell ND 
Patient no.LGL lymphocytosisGeneQuantitative follow-upLymphocyte populationCell-surface TCR expression
Yes Incomplete TCRD Yes NK cell NA 
Yes Complete TCRG Yes CD8+ T cell TCR αβ+ 
Yes Incomplete TCRD Yes CD8+ T cell ND 
Yes Complete TCRD Yes CD8+ T cell TCR γδ+ 
Yes Complete TCRG Yes CD4+ T cell TCR αβ+ 
Yes Complete TCRG Yes CD4+ T cell ND 
Yes Incomplete TCRD No NK cell NA 
Yes Incomplete TCRD Yes CD4+ T cell TCR γδ+ 
Yes Complete TCRG Yes CD4+ T cell TCR αβ+ 
Yes Incomplete TCRD No NK cell NA 
Yes Incomplete TCRD No NK cell NA 
Yes Complete TCRG Yes CD8+ T cell ND 
10 Yes Incomplete TCRD No ND ND 
10 Yes Complete TCRG No CD8+ T cell ND 
12 No Complete TCRG Yes ND ND 
17 No Complete TCRG No CD8+ T cell ND 
18 No Complete TCRG Yes CD8+ T cell ND 
18 No Complete TCRG Yes CD8+ T cell ND 

To quantify the amount of lymphocyte clone in correlation with the lymphocyte count and to identify the lymphocyte fraction where clonal cells reside, patient-specific ASO primers were designed for 11 patients. Patients 1 to 10 had persistent lymphocytosis with large granular lymphocyte (LGL) morphology during dasatinib treatment. In patients 12, 17, and 18, lymphocyte counts were normal during the therapy. No sorting was done from patient 12 because of small number of cells.

NK cell indicates CD3neg CD16/56+; CD8+ T cell, CD3+CD8+; CD4+ T cell, CD3+CD8neg; ND, not done; and NA, not applicable.

Clonal TCR γ and δ gene rearrangements were found in distinct lymphocyte subclasses

Analysis of clonal TCR γ and δ gene rearrangements from the magnetic bead–sorted CD8+ and CD8neg cells showed that clones can be detected in both cell populations. To further elucidate the specific cell populations, samples underwent fluorescence-activated cell sorting (FACS) into pure CD4+, CD8+, NK- and B-cell fractions (Figure 1). Sorting and further analysis were performed from 8 LGLpos and 2 LGLneg patients (Table 4).

Analysis with patient-specific ASO primers showed that most patients had clonal rearrangements in the CD8+ cell population, including the 2 LGLneg patients (Table 4). Strikingly in 4 of 6 patients with LGL lymphocytosis who had a clonal TCR δ gene rearrangement, the clonal lymphocyte population resided in the NK-cell fraction. Other fractions from the same samples (CD4+, CD8+, and B cells) were negative for TCR δ gene rearrangements, confirming the specificity. Two other patients with TCR δ gene rearrangements had clonal cells in the γδ+ T-cell population (patient 5 in CD4+ γδ+ T-cell fraction and patient 2 in CD8+ γδ+ T-cell fraction). Thus, clonal TCR δ gene rearrangements were detected only in NK cells and in γδ+ T cells. However, no TCR δ protein was expressed on the NK-cell surface, as assessed by flow cytometry. Sequence alignments of clonal TCR δ gene rearrangements are presented in Table 5.

Table 5

Sequences of clonal TCR δ-gene rearrangements detected in LGLpos patients

Patient no.Clonal cell populationVδ2/Vδ3N1Dδ1N2Dδ2N3Dδ3N4Function of rearrangement and junction region amino acids (complete and productive rearrangements)
Germline  Vδ2 tgtgcctgtgacacc Vδ3 ctactgtgcctttag  gaaatagt  ccttcctac  actgggggatacg  acaccgataaactcatc  
NK cell Vδ2 tgtgcctgt attt     actgggggatacg   Incomplete (no J gene); unproductive 
CD8+ Vδ2 tgtgcctgtgacacc gaagac     ctgggggata aggctc caccgataaactcatc Unproductive (stop codons, out-of-frame junction) 
TCR γδ+ CD8+ Vδ3 ctactgtgccttta  atag cgt ttcctac ggggtttg gggggata atgg cgataaactcatc Productive CAFNSVSYGVWGDNGDKLIF 
NA Vδ2 tgtgcctgtgacacc gtatt     actgggggatacg cggcg caccgataaactcatc Productive CACDTVLLGDTRRTDKLIF 
NK cell Vδ2 tgtgcctgtgac ttcttcccttttg     ctgggggatacg   Incomplete (no J gene); unproductive 
TCR γδ+ CD4+     ccttccta actggagggg   accgataaactcatc Incomplete (no V gene); unproductive 
NK cell Vδ2 tgtgcctgtgacacc gtgt     tgggggatacg   Incomplete (no J gene); unproductive 
NK cell Vδ2 tgtgcctgtgacac gggct     actgggggatacg   Incomplete (no J gene); unproductive 
NA Vδ2 tgtgcctgt tctgtacccgt     actgggggatacg   Incomplete (no J gene); unproductive 
10 NA Vδ2 tgtgcctgtgac cgtt     actgggggatacg   Incomplete (no J gene); unproductive 
Patient no.Clonal cell populationVδ2/Vδ3N1Dδ1N2Dδ2N3Dδ3N4Function of rearrangement and junction region amino acids (complete and productive rearrangements)
Germline  Vδ2 tgtgcctgtgacacc Vδ3 ctactgtgcctttag  gaaatagt  ccttcctac  actgggggatacg  acaccgataaactcatc  
NK cell Vδ2 tgtgcctgt attt     actgggggatacg   Incomplete (no J gene); unproductive 
CD8+ Vδ2 tgtgcctgtgacacc gaagac     ctgggggata aggctc caccgataaactcatc Unproductive (stop codons, out-of-frame junction) 
TCR γδ+ CD8+ Vδ3 ctactgtgccttta  atag cgt ttcctac ggggtttg gggggata atgg cgataaactcatc Productive CAFNSVSYGVWGDNGDKLIF 
NA Vδ2 tgtgcctgtgacacc gtatt     actgggggatacg cggcg caccgataaactcatc Productive CACDTVLLGDTRRTDKLIF 
NK cell Vδ2 tgtgcctgtgac ttcttcccttttg     ctgggggatacg   Incomplete (no J gene); unproductive 
TCR γδ+ CD4+     ccttccta actggagggg   accgataaactcatc Incomplete (no V gene); unproductive 
NK cell Vδ2 tgtgcctgtgacacc gtgt     tgggggatacg   Incomplete (no J gene); unproductive 
NK cell Vδ2 tgtgcctgtgacac gggct     actgggggatacg   Incomplete (no J gene); unproductive 
NA Vδ2 tgtgcctgt tctgtacccgt     actgggggatacg   Incomplete (no J gene); unproductive 
10 NA Vδ2 tgtgcctgtgac cgtt     actgggggatacg   Incomplete (no J gene); unproductive 

The table represents detected TCR δ rearrangements. Sequences of the junction region (VDJ) are aligned.

Clonal lymphocytes are BCR-ABL1 negative

To determine whether the clonal lymphocytes belonged to the Ph+ leukemic clone, FISH with a BCR-ABL1 fusion gene probe was performed from the diagnostic phase samples from 2 patients with CML (patients 7 and 17; Table 1). From these patients CD4+, CD8+, NK-, and B-cell populations underwent FACS, and the cell populations were studied separately with FISH. In the first patient, 1% to 2% of cells were Ph+ in CD4+, CD8+, and NK-cell fractions. In B-cell fraction up to 9% of cells were Ph+. In the second patient, all studied lymphocyte populations were negative for the Ph chromosome. This is in accordance with an earlier publication by Takahashi et al37  who have shown that in untreated CML patients T and NK cells are usually negative for the Ph chromosome.

Furthermore, during dasatinib and imatinib therapy, 59% (17 of 29) of the patients with clonal TCR γ/δ rearrangements were negative for BCR-ABL1 transcripts in blood by RQ-PCR, and in 5 patients also high-resolution FISH analysis was performed (1000 cells counted) and no Ph+ cells could be detected. Thus, it can be concluded that the detected clonal lymphocytes did not belong to the malignant Ph+ clone.

CMV seropositivity and clonal lymphocytosis

Of 23 patients who had clonal TCR rearrangements and CMV serology data available, 21 (91%) were positive for CMV immunoglobulin G (IgG; Table 1). Only 2 of 6 patients without clonal TCR rearrangement had a positive CMV IgG result. Patients with LGL lymphocytosis during dasatinib treatment were all CMV IgG positive. Only 50% (4 of 8) of LGLneg patients were CMV IgG positive, and none of the CMV-negative patients had clonal TCR rearrangements. However, 2 patients taking imatinib, who were CMV IgG negative, had clonal TCR rearrangements (patients 25 and 31; Tables 12).

According to the tumor immune surveillance hypothesis, expansion of occult malignant clones is prevented by the concerted action of innate and adaptive immune system. The development of clinical disease, such as CML, requires an escape from immune recognition through a multifaceted process of immunoediting whereby tumor-reactive cytotoxic cells are either deleted or rendered anergic.38  In accord, PR-1 leukemia antigen reactive CD8+ T cells have been isolated from patients with CML but were shown to be dysfunctional because of a selective deletion of high-avidity clones by apoptosis.39,41  Recently, in a biologically relevant CML mouse model, leukemia-specific T cells were shown to be exhausted, maintained only limited cytotoxicity, and expressed high levels of the inhibitory receptor PD-1. Similar overexpression of PD-1 was observed in CD8+ cells from patients with CML.42  However, because CML is particularly responsive to immunomodulatory therapies, such as interferon α and donor lymphocyte infusions, it is probable that immunologic defense mechanisms have not been permanently compromised.

Recent data from our group and other groups have suggested that dasatinib has immunostimulatory effects in the form of persistent monoclonal/oligoclonal LGL lymphocytosis in a distinct proportion of patients.25,26  The striking association between LGL expansion and excellent therapy response raised the possibility of TKI-mediated induction of cellular immunity against leukemic antigens. Because the phenotype of the expanding cytotoxic lymphocytes (CD45RO+CD27negCD62Lneg) was in accordance with a preexisting long-lived effector memory cell, we wanted to examine the prevalence of clonal lymphocytes before the start of dasatinib therapy and at the time of CML diagnosis. Unexpectedly, we found lymphocytes with clonal TCR rearrangements in most (83%) patients with CML at diagnosis. Because the sensitivity of the assay is 1% to 5%, a significant proportion of lymphocytes were clonal in untreated patients with CML. The diagnostic phase lymphocyte clones persisted at low levels during imatinib therapy, but they markedly expanded in a proportion of dasatinib-treated patients. These findings strengthen the hypothesis that dasatinib-associated LGL lymphoproliferation is an expansion of preexisting T-memory cell clones present already at the time of diagnosis.

Rearrangements in the gene segment that code for variable TCR regions are responsible for the enormous diversity of antigen-specific receptors in T cells. These receptors are generated during differentiation of T cells by rearrangements of variable (V), diversity (D) (not found in TCR γ gene) and junction (J) gene segments for each lymphocyte. In each person there can be more than 107 different T-cell clones, which constitute a unique and diverse lymphocyte repertoire. Therefore, significant expansions of single-lymphocyte clones are uncommon in healthy persons. Expanded clonotypes of CD4+ or CD8+ cells can be detected with a high frequency only in older persons and are almost exclusively confined to the CD45RO+ memory subset.43,44  Clonal expansions have not been related to particular Vβ families, but are composed of several TCR Vβ families that vary from person to person, suggesting that a multiplicity of antigenic stimulations are involved in the selection of the expanded clones.43  Similarly, in our material, in only 1 of 12 healthy controls a clonal TCR γ gene rearrangement could be found. The high frequency of clonal lymphocytes at CML diagnosis was not related to the older age of patients, because the median age was 51 years in the diagnosis phase patient group compared with 46 years in healthy controls. However, a potential association was observed between positive CMV IgG serology and clonal TCR rearrangements because more than 90% of patients with clonal TCR rearrangements were CMV IgG positive, whereas only 2 of 6 patients without clonal TCR rearrangements were CMV positive. In our previous publication we also showed that in patients who developed LGL lymphocytosis during dasatinib therapy, more than 40% had CMV reactivation during the treatment. Additional studies are warranted to address the role of CMV in this setting.

Rearrangement of TCR genes is considered to be restricted to T cells. However, incomplete TCR δ gene rearrangements have been described to occur in 16% of alleles in B lymphocytes of healthy controls, indicating that the TCR genes are not exclusively rearranged in T cells.45  Furthermore, Fronkova et al46  demonstrated that TCR δ gene rearrangements can occur also in NK cells. This is well in accordance with our results because we detected clonal TCR δ gene rearrangements in the NK-cell fraction of patients with LGL lymphocytosis with NK-cell phenotype. None of the patients had clonal TCR γ gene rearrangement in NK cells. Note that the analysis of TCR gene rearrangements was informative in selected patients with NK-cell phenotype, because NK-cell clonality is notoriously difficult to assess. In addition, this strengthens the view that dasatinib-associated LGL lymphocytosis in patients with NK-cell phenotype is also a clonal or oligoclonal phenomenon similar as in patients with T-cell phenotype.

T cells expressing the α/β chains on the cell surface rearrange first γ and δ genes and thereafter α and β genes, which leads to the formation of the functional protein on the cell surface. TCR δ gene is spliced out during TCR α gene rearrangement. More than 90% of T cells in healthy persons express α/β chains on the surface, and γδ+ T cells are the minority. In a subgroup of patients we observed clonal TCR δ gene rearrangements also among T-cell fraction. Further sorting of T cells into αβ+ and γδ+ T cells showed that clonal cells showing TCR δ gene rearrangements were confined to the γδ+ T-cell fraction. Thus, dasatinib patients with LGL lymphocytosis had more often clonal TCR δ gene rearrangements than patients without lymphocytosis (90% vs 10%, respectively), suggesting that patients with LGL lymphocytosis have an expansion of γδ+ T-cell or NK-cell population. The importance and function of NK and γδ+ T cells in cancer immunosurveillance have been unclear until recently.47,48  These cells of the innate immune system are important effectors in the control of hematologic malignancies and can eliminate minimal residual disease in CML.49,50 

To our knowledge, this is the first report on clonal cytotoxic lymphocytes in patients with CML at the time of diagnosis and during TKI therapy. Because the lymphocytes did not belong to the malignant Ph+ clone, their role as a part of anergic immune surveillance machinery requires further studies. Clonal lymphocytes not belonging to the leukemic clone have been described in other hematologic malignancies (acute promyelocytic leukemia, myelodysplastic syndrome) as well.32,51  In our previous report on patients with advanced-phase CML and Ph+ acute lymphoblastic leukemia being treated with dasatinib, clonal LGL lymphocytosis was associated with excellent treatment responses. Similarly, in patients with multiple myeloma, the presence of clonal T cells was related to superior prognosis.52  In accord, long-lasting LGL expansions with clonal TCR γ/δ gene rearrangements have been described in a subset of patients receiving an allogeneic stem cell transplant, which were associated with better overall survival, suggesting a graft-versus-leukemia activity.53,54  We, therefore, speculate that dasatinib treatment reverts the tolerance mechanism and restores the function of unresponsive, exhausted leukemia-specific cytotoxic cells. Our previous results showed that patients with LGL lymphocytosis being treated with dasatinib have a decreased amount of regulatory T cells.26  This observation was confirmed in the current study population (data not shown) and could be one factor facilitating the restoration of T-cell function.

In conclusion, clonal lymphocytes were frequently present in patients with CML at diagnosis and persisted at low levels during TKI therapy. In a distinct subgroup of dasatinib-treated patients, clonal cells markedly expanded during therapy. Expanding clones were not only confined to CD8+ cytotoxic cells but also resided in NK- and γδ+ T-cell fractions. These cells may participate in the elimination of the residual CML cells, because previous studies have linked clonal expansions with excellent, long-lasting therapy responses in dasatinib-treated patients with advanced phase leukemia. The isolation of epitopes and detailed functional analyses of clonal, CML-associated lymphocytes are ongoing.

An Inside Blood analysis of this article appears at the front of this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

We thank Drs J. Vakkila and P. Arstila for valuable comments on the paper. We also thank the personnel at the Hematology Research Unit Helsinki and the Laboratory of Molecular Genetics at Turku University Central Hospital for their expert clinical and technical assistance.

This work was supported by the Finnish special governmental subsidy for health sciences, research, and training and by the Finnish Cancer Societies, Emil Aaltonen Foundation, Academy of Finland, Finnish Medical Foundation, Blood Disease Foundation, Biomedicum Helsinki Foundation, Finnish Association of Hematology, Gyllenberg Foundation, and K. A. Johansson Foundation.

Contribution: A.K. performed the laboratory analyses; A.K., K.P., and S.M. designed the study, analyzed the data, and wrote the paper; V.J. and V.K. supervised the molecular studies and participated in the data analysis; M.E. and L.S. provided patient samples for analysis and participated in the data analysis; and R.S. participated in the design of the study and analysis of the data.

Conflict-of-interest disclosure: K.P. has received research funding and honoraria from Novartis and Bristol-Myers Squibb. M.E., R.S., and S.M. have received honoraria from Bristol-Myers Squibb. The remaining authors declare no competing financial interests.

Correspondence: Satu Mustjoki, Hematology Research Unit, Biomedicum Helsinki, PO Box 700, FIN-00029 HUCH, Helsinki, Finland; e-mail: satu.mustjoki@helsinki.fi.

1
Hochhaus
A
O'Brien
SG
Guilhot
F
et al
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Leukemia
2009
23
6
1054
1061
2
Druker
BJ
Guilhot
F
O'Brien
SG
et al
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
N Engl J Med
2006
355
23
2408
2417
3
Apperley
JF
Cortes
JE
Kim
DW
et al
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
J Clin Oncol
2009
27
21
3472
3479
4
Hochhaus
A
Baccarani
M
Deininger
M
et al
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Leukemia
2008
22
6
1200
1206
5
Kantarjian
HM
Giles
F
Gattermann
N
et al
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood
2007
110
10
3540
3546
6
Hantschel
O
Rix
U
Schmidt
U
et al
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Proc Natl Acad Sci U S A
2007
104
33
13283
13288
7
Rix
U
Hantschel
O
Durnberger
G
et al
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Blood
2007
110
12
4055
4063
8
Bantscheff
M
Eberhard
D
Abraham
Y
et al
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
Nat Biotechnol
2007
25
9
1035
1044
9
Schade
AE
Schieven
GL
Townsend
R
et al
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
Blood
2008
111
3
1366
1377
10
Fei
F
Yu
Y
Schmitt
A
et al
Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
Exp Hematol
2008
36
10
1297
1308
11
Blake
S
Hughes
TP
Mayrhofer
G
Lyons
AB
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
Clin Immunol
2008
127
3
330
339
12
Weichsel
R
Dix
C
Wooldridge
L
et al
Profound inhibition of antigen-specific T-cell effector functions by dasatinib.
Clin Cancer Res
2008
14
8
2484
2491
13
Fei
F
Yu
Y
Schmitt
A
et al
Dasatinib inhibits the proliferation and function of CD4+CD25+ regulatory T cells.
Br J Haematol
2009
144
2
195
205
14
Seggewiss
R
Lore
K
Greiner
E
et al
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Blood
2005
105
6
2473
2479
15
Seggewiss
R
Price
DA
Purbhoo
MA
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update.
Cytotherapy
2008
10
6
633
641
16
Dietz
AB
Souan
L
Knutson
GJ
Bulur
PA
Litzow
MR
Vuk-Pavlovic
S
Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.
Blood
2004
104
4
1094
1099
17
Cwynarski
K
Laylor
R
Macchiarulo
E
et al
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.
Leukemia
2004
18
8
1332
1339
18
Chen
J
Schmitt
A
Chen
B
et al
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.
J Cell Mol Med
2008
12
5B
2107
2118
19
Blake
SJ
Bruce Lyons
A
Fraser
CK
Hayball
JD
Hughes
TP
Dasatinib suppresses in vitro natural killer cell cytotoxicity.
Blood
2008
111
8
4415
4416
20
Mattiuzzi
GN
Cortes
JE
Talpaz
M
et al
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Clin Cancer Res
2003
9
3
976
980
21
Savani
BN
Montero
A
Kurlander
R
Childs
R
Hensel
N
Barrett
AJ
Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Bone Marrow Transplant
2005
36
11
1009
1015
22
Al-Ameri
A
Kantarjian
H
Borthakur
G
et al
Opportunistic infections are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract].
Blood
2009
114
22
Abstract 1120
23
Al-Ameri
A
Kantarjian
H
Burton
E
et al
Low risk of infectious events in patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) treated with dasatinib [abstract].
Blood
2009
114
22
Abstract 3291
24
Sillaber
C
Herrmann
H
Bennett
K
et al
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
Eur J Clin Invest
2009
39
12
1098
1109
25
Kim
DH
Kamel-Reid
S
Chang
H
et al
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
Haematologica
2009
94
1
135
139
26
Mustjoki
S
Ekblom
M
Arstila
TP
et al
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Leukemia
2009
23
8
1398
1405
27
Kronenberg
A
Seebach
JD
Bossart
W
Weber
R
Polyclonal proliferation of large granular lymphocytes during cytomegalovirus primary infection in a human immunodeficiency virus-infected patient receiving antiretroviral therapy.
Clin Infect Dis
2001
33
5
E34
E36
28
Smith
PR
Cavenagh
JD
Milne
T
et al
Benign monoclonal expansion of CD8+ lymphocytes in HIV infection.
J Clin Pathol
2000
53
3
177
181
29
Hingorani
R
Choi
IH
Akolkar
P
et al
Clonal predominance of T cell receptors within the CD8+ CD45RO+ subset in normal human subjects.
J Immunol
1993
151
10
5762
5769
30
Raitakari
M
Brown
RD
Sze
D
et al
T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells.
Br J Haematol
2000
110
1
203
209
31
Epling-Burnette
PK
Painter
JS
Rollison
DE
et al
Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome.
Leukemia
2007
21
4
659
667
32
Li
Y
Chen
S
Yang
L
et al
Clonal expanded TCR Vbeta T cells in patients with APL.
Hematology
2005
10
2
135
139
33
Aw
D
Silva
AB
Palmer
DB
Immunosenescence: emerging challenges for an ageing population.
Immunology
2007
120
4
435
446
34
Pongers-Willemse
MJ
Seriu
T
Stolz
F
et al
Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Leukemia
1999
13
1
110
118
35
IMGT: ImMunoGeneTics database
Accessed September 1, 2009
36
National Center for Biotechnology Information
Blast.
Basic Local Alignment Search Tool
Accessed September 1, 2009
37
Takahashi
N
Miura
I
Saitoh
K
Miura
AB
Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization.
Blood
1998
92
12
4758
4763
38
Dunn
GP
Old
LJ
Schreiber
RD
The immunobiology of cancer immunosurveillance and immunoediting.
Immunity
2004
21
2
137
148
39
Molldrem
JJ
Lee
PP
Kant
S
et al
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.
J Clin Invest
2003
111
5
639
647
40
Molldrem
JJ
Lee
PP
Wang
C
et al
Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.
Nat Med
2000
6
9
1018
1023
41
Rezvani
K
Grube
M
Brenchley
JM
et al
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
Blood
2003
102
8
2892
2900
42
Mumprecht
S
Schurch
C
Schwaller
J
Solenthaler
M
Ochsenbein
AF
Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.
Blood
2009
114
8
1528
1536
43
Wack
A
Cossarizza
A
Heltai
S
et al
Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets.
Int Immunol
1998
10
9
1281
1288
44
Muche
JM
Sterry
W
Gellrich
S
Rzany
B
Audring
H
Lukowsky
A
Peripheral blood T-cell clonality in mycosis fungoides and nonlymphoma controls.
Diagn Mol Pathol
2003
12
3
142
150
45
Krejci
O
Prouzova
Z
Horvath
O
Trka
J
Hrusak
O
Cutting edge: TCR delta gene is frequently rearranged in adult B lymphocytes.
J Immunol
2003
171
2
524
527
46
Fronkova
E
Krejci
O
Kalina
T
Horvath
O
Trka
J
Hrusak
O
Lymphoid differentiation pathways can be traced by TCR delta rearrangements.
J Immunol
2005
175
4
2495
2500
47
Ferrarini
M
Ferrero
E
Dagna
L
Poggi
A
Zocchi
MR
Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer.
Trends Immunol
2002
23
1
14
18
48
Girardi
M
Immunosurveillance and immunoregulation by gammadelta T cells.
J Invest Dermatol
2006
126
1
25
31
49
Siegers
GM
Al-Beirouti
B
Mathieson
A
et al
Gamma delta T cells (GDTCs) to eliminate minimal residual disease (MRD) in chronic myeloid leukemia (CML): a pre-clinical model [abstract].
Blood
2008
11
112
Abstract 574
50
Zocchi
MR
Poggi
A
Role of gammadelta T lymphocytes in tumor defense.
Front Biosci
2004
9
2588
2604
51
Farace
F
Orlanducci
F
Dietrich
PY
et al
T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions.
J Immunol
1994
153
9
4281
4290
52
Brown
RD
Yuen
E
Nelson
M
Gibson
J
Joshua
D
The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma.
Leukemia
1997
11
8
1312
1317
53
Mohty
M
Faucher
C
Vey
N
et al
Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis.
Leukemia
2002
16
10
2129
2133
54
Ramesh
M
Al-Kadhimi
Z
Mellon-Reppens
S
et al
T-cell large granular lymphocyte (T-LGL) expansion post adult allogeneic hematopoietic stem cell transplantation (HSCT)–‘A Prognostic Indicator for Improved Overall Survival’ [abstract].
Blood
2009
114
22
Abstract 2241